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1. Introduction 
One-third of the world’s population is latently infected with mycobacterium tuberculosis 
(MTb).(Raviglione et al., 1995; 2010c) Of those infected a 5% to 10% chance exists during that 
person’s lifetime for the disease to become active.(Corbett et al., 2003) Patients who are 
immunocompromised have a much greater risk of experiencing active tuberculosis. Patients 
who have contracted human immunodeficiency virus (HIV) have a 10% chance yearly of 
developing active disease. Tuberculosis (TB) is the most common opportunistic infection in 
patients with HIV.(2010a) A person with HIV is 20-30 times more likely to develop active 
tuberculosis than a person without the virus. (2010b) The World Health Organization (WHO) 
states that tuberculosis is the leading infectious killer in HIV-positive patients worldwide, 
killing one out of every four patients. 
Guidelines recommend treating both infections concurrently as this has shown an increased 
probability of survival versus sequential therapy.(2010a; Abdool Karim et al., 2010) 
Unfortunately, several problems arise when combining therapy. Both disease states require 
multidrug regimens for long durations of time. TB is generally treated for nine or more 
months in patients with dual disease states, while HIV is treated for a lifetime. Not only 
does the combination of regimens lead to multi-way drug interactions, but to overlapping 
side effects, the immune reconstitution inflammatory syndrome (IRIS), and subsequently an 
increased difficulty on the part of the patient to adhere to the complicated regimens, which 
ultimately may result in viral or bacterial resistance.  
The current recommendations for treating tuberculosis in HIV patients are the same as 
treatment in patients without HIV: an initial two month phase of isoniazid, pyrazinamide, 
ethambutol and rifampin or rifabutin followed by an extended four month phase of 
isoniazid and one of the rifamycins. In HIV patients the duration may be substantially 
longer. While each of the rifamycins have significant Cytochrome P450 (CYP450) 
interactions, rifabutin is considered to have the least among the three and therefore the best 
choice to be used in treating tuberculosis in HIV patients. (Piscitelli and Gallicano, 2001)  
Rifabutin is not available in many parts of the world which need it most, specifically low-
resource countries (e.g., many sub-Saharan Africa nations). Also, many of the antiretrovirals 
which are necessary to treat AIDS are not available.  
With multiple drug interactions, overlapping toxicities, and an unknown pharmacokinetic 
response in individual patients, clinicians are often at a disadvantage in making treatment 
decisions. Monitoring of serum concentrations could help elucidate sub- or supra-
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therapeutic concentrations of not only the rifamycins but co-administered HIV medications, 
leading to a more optimal dosing of medications, reduced toxicities, and a decreased 
likelihood of drug resistance. In this chapter we will discuss the co-pathophysiology of HIV 
and TB, the interactions among the rifamycins and HIV medications, and how therapeutic 
drug management (TDM), also known as therapeutic drug monitoring, may aid the clinician 
in making informed clinical decisions. 
2. Interrelated pathophysiology 
The specific pathways by which TB and HIV impact each other have yet to be fully 
elucidated. (Patel et al., 2007)  CD4+ T-helper cells in the body activate macrophages which 
engulf MTb. In an immunocompetent patient alveolar macrophages undergo apoptosis to 
destroy MTb. With HIV infection macrophages are prevented from initiating apoptosis. 
Alternatively, TB-infected macrophages express tumor necrosis factor-alpha (TNF-ǂ) which 
leads to an increase in HIV replication. As HIV replication increases, TB is no longer well 
contained. The clinical course of TB accelerates which may lead to extrapulmonary 
involvement. In short, the combination of the two disease states begins a vicious cycle which 
ultimately leads to an increased risk of mortality. 
3. The rifamycins  
The first rifamycins were isolated in 1957 from the bacterium Streptomyces mediterranei (now 
Amycolatopsis rifamycinica).(Margalith, 1960)  Since their discovery they have been used in the 
treatment of numerous diseases including: methicillin-resistant Staphylococcus aureus (MRSA), 
leprosy, Legionnaires’ disease, and, of course, TB. The rifamycins currently available for 
treatment of TB are rifampin, rifabutin, and rifapentine. They are considered the most 
important drugs for the treatment of TB due to their potent sterilizing effect on MTb. Briefly, 
the sterilizing effect is the ability of a TB drug to prevent post-treatment relapses. Regimens 
without a rifamycin or not using a rifamycin for at least six months have increased rates of 
treatment failure.(Okwera et al., 1994; Jindani et al., 2004) A meta-analysis by Khan et al. 
reported that patients using regimens with a rifamycin for only two months were much more 
likely to experience relapse than those patients on a regimen consisting of a rifamycin for at 
least eight months.(Khan et al., 2010) The rifamycins act by inhibiting the DNA dependent 
RNA polymerase encoded by the rpoB gene. The rifamycin binds to the ǃ-subunit and blocks 
the synthesis of the RNA chain. Importantly, the drugs do not inhibit the mammalian enzyme. 
In regards to the rifamycin family, rifampin is the fastest absorbed with the highest 
bioavailability, while rifapentine has the slowest absorption and a half-life Intermediate 
(~13.19h) (1998) between the short half-life of rifampin (~2.46h) (2004 Jan) and the long 
terminal elimination half-life of rifabutin (~45h)(2010 Jan). 
3.1 Rifampin 
Rifampin has been used in the treatment of TB for nearly half a century. Along with 
isoniazid, rifampin is considered the cornerstone for successful treatment. However, 
rifampin’s potent inductive effects on many hepatic and intestinal enzymes as well as the 
drug transporter, P-glycoprotein, generate many drug interactions. With regards to HIV 
treatment, rifampin interacts with the non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), the protease inhibitors (PIs), the integrase inhibitors (e.g., raltegravir), and the 
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entry inhibitors (e.g., maraviroc).  Ideally, rifabutin is substituted for rifampin in HIV 
patients. Unfortunately, rifabutin is not available in most resource-poor countries who 
cannot afford the newer rifamycin. Also, unlike rifampin, rifabutin is not available in a 
multidrug capsule (e.g., Rifater®: rifampin, isoniazid, pyrazinamide) which aids adherence. 
Thus, drug interactions between rifampin and HIV medications must be managed. In this 
chapter we will limit our discussion to rifampin’s interactions with the NNRTIs and the PIs 
as these are the most commonly used medications for HIV treatment.   
3.1.1 Rifampin & the PIs 
Due to its inhibitory effects on CYP enzymes, ritonavir is generally prescribed at a low dose 
with a second PI (also known as ritonavir “boosting”). (King et al., 2004; Burger et al., 2006b)  
As rifampin’s inductive effects are especially strong with the PIs, only two formulations 
approach therapeutic concentrations when given concomitantly with rifampin: lopinavir 
and saquinavir, both of which must be administered with substantial doses of ritonavir. 
(Maartens et al., 2009) 
The standard dose of lopinavir-ritonavir is 400/100 mg given twice daily. When administered 
with the standard 600 mg dose of rifampin, Bertz et al. noted a substantial reduction in Cmax 
(45%), AUC (75%) and Cmin (99%). (Bertz R, 2001)  Building upon this observation, La Porte et 
al. performed a study with 32 healthy volunteers to compare the pharmacokinetics of the 
standard lopinavir-ritonavir dose given without rifampin with two dose-adjusted regimens: 
800/200 mg twice daily and 400/400 mg twice daily of lopinavir/ritonavir with rifampin. (la 
Porte et al., 2004) Lopinavir concentrations were markedly higher in the adjusted regimens, 
when compared to the reported data for standard doses. However, the authors could not 
demonstrate that the adjusted regimens were equivalent to lopinavir-ritonavir without 
rifampin. This may be due to rifampin’s inductive effects, or limitations of the study (e.g., 
small sample size). Regardless, the study indicates that super-boosted lopinavir-ritonavir may 
be an option for co-infected patients when alternative regimens are unavailable. The Cmax, 
AUC0-12, and Cmin for lopinavir during therapy composed by lopinavir-ritonavir 400/400 mg 
after 10 and 24 days, respectively, were: 12.3 and 11.5 mg/liter; 102.9 and 100.7 mg*h/liter; 5.2 
and 5.9 mg/liter. The lopinavir Cmax, AUC0-12 and Cmin for the lopinavir-ritonavir 800/200 mg 
regimen after days 10 and 24 were:  12.9 and 13.8 mg/liter; 111.8 and 104.5 mg*h/liter and 
6.5 and 5.1 mg/liter, respectively. Of note, the authors point out that 31% of the patients 
stopped treatment with the adjusted regimens due to side effects, primarily elevated liver 
function tests (LFTs). In patients co-infected with HIV and TB who must receive the 
medications for a greater amount of time and/or additional potential hepatotoxic drugs 
these side effects may be exacerbated.  
In a study of ten healthy volunteers, rifampin reduced the concentration of atazanavir 
significantly for both 300 and 400 mg doses given BID. (Acosta et al., 2007) A larger study 
with 71 healthy volunteers revealed that ritonavir was not able to overcome rifampin’s 
induction. The following proportions of atazanavir-ritonavir were analyzed: 300/100 mg, 
300/200 mg and 400/200 mg, in combination with 600 mg of rifampin. (Burger et al., 2006b) 
These dosage regimens were compared with the administration of just atazanavir 400 mg or 
with the combination atazanavir-ritonavir 300/100 mg. The comparisons showed significant 
reductions in Cmax and AUC. However, the reductions in Cmin were the most significant: 
around 60% for the regimens when compared with just atazanavir 400 mg and greater than 
90% for the three regimens when compared to the combination atazanavir-ritonavir 300/100 
mg. The obtained atazanavir Cmin were: 15.9 ng/mL (300/100/600 mg-atazanavir/ 
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ritonavir/rifampin), 40.6 ng/mL (300/200/600 mg-atazanavir/ritonavir/rifampin) and 74.4 
ng/mL (400/200/600 mg-atazanavir/ritonavir/rifampin). Another study from Mallolas and 
collaborators confirmed these results. (Mallolas et al., 2007) The researchers performed a 
study in patients with HIV to verify the feasibility of a regimen with 600 mg of rifampin 
combined with 300/100 of atazanavir-ritonavir. The study had to be interrupted because of 
very low concentrations of atazanavir. The median reductions in Cmax, AUC, and Cmin for 
the three patients that completed the treatment were 48, 64, and 100%, respectively. 
In a study of 22 patients co-infected with TB and HIV, Ribera et al. found that saquinavir 
was reduced substantially in the presence of rifampin. (Ribera et al., 2007) Patients were 
treated with the standard TB regimen of rifampin, isoniazid, pyrazinamide, and with or 
without ethambutol for two months. Ethambutol and pyrazinamide were then dropped 
from the regimen and once-daily antiretroviral (ART) added. ART consisted of 1600 mg 
saquinavir, and 200 mg ritonavir along with didanosine and lamivudine. The saquinavir 
pharmacokinetic parameters Cmax, AUC0-24, and Cmin were reduced by 35%, 40% and 49%, 
respectively. The obtained saquinavir Cmax, AUC0-24, Cmin were 2.1 μg/mL, 13.6 μg*h/mL 
and 0.06 μg/mL, respectively. The authors concluded that twice-daily administration of 
saquinavir or higher doses might result in therapeutic concentrations, but it is unknown 
what doses would be necessary. A study of 30 co-infected HIV/TB patients given 400 mg 
saquinavir and 400 mg ritonavir plus two NRTIs suggests that these doses are able to 
maintain therapeutic concentrations of rifampin and the PIs; however, the study had a 
substantial attrition rate with ten patients dropping out during TB therapy and another 
fifteen patients dropping when ART was added. (Rolla et al., 2006) 
Hepatotoxicity is one of the primary concerns facing clinicians when using a saquinavir-
containing regimen with the rifamycins. A 2009 two-period crossover study consisting of 28 
healthy volunteers received either 600 mg rifampin once daily or 1000/100 mg saquinavir-
ritonavir twice daily for two weeks. (Schmitt et al., 2009) Volunteers then received all three 
drugs for two weeks. All patients in the arm who initially received rifampin and 
subsequently received saquinavir-ritonavir experienced elevations in their alanine 
aminotransferases (ALTs) from 11 to 70 times the upper limit of normal, prompting an early 
termination of the study.  
In a study of six HIV patients, ritonavir (100mg - BID) was not able to overcome the 
induction caused by rifampin (300 mg – half of the normal dose) in indinavir (800 mg - BID) 
metabolism. An 87% reduction in the indinavir concentration and a 94% reduction in 
ritonavir concentration was verified 12 hours after the last dose. (Justesen et al., 2004 ) This 
study detected a Cmax of 10,116 ng/mL and Cmin of 112 ng/mL (both quantified 4 days after 
rifampin administration). The AUC was not calculated. 
In short, ritonavir’s effect on overcoming the induction caused by rifampin is variable 
according to the co-administered PI and the dosage schemes have to be carefully chosen in 
order to achieve therapeutic drug concentrations. Also, it is important to consider the 
possible hepatotoxicity which may occur with increased dosing. 
3.1.2 Rifampin & the NNRTIs 
Efavirenz is primarily metabolized by CYP2B6 and to a lesser extent by CYP3A4 and 
CYP2A6 to inactive metabolites. (Kwara et al., 2010; Rakhmanina and van den Anker, 2010) 
As rifampin is a potent inducer of CYP2B6, concern exists regarding efavirenz 
concentrations when the two are given concurrently, considering that subtherapeutic 
efavirenz concentrations could lead to treatment failure and resistance. This hypothesis was 
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based on previous studies where reduced efavirenz concentrations caused treatment failure. 
In a study performed by Marzolini and collaborators virological failure was associated with 
low plasma concentrations in 50% of the patients on efavirenz (Cmin<1000 µg/L) while CNS 
toxicity was three times more frequent in patients with high efavirenz concentrations 
(Cmin>4000 µg/L). (Marzolini et al., 2001) The drug concentrations were determined 
between 8 and 20 hours post dose and the concentrations varied from 125 to 15,230 μg/L. 
The drug is administered at bedtime because of its side effects, therefore it is difficult to 
determine the real Cmin. Efavirenz CNS toxicity occurs in approximately 20-40% (Gazzard, 
1999) of patients, manifesting as light-headedness, feeling faint, dizzy, “out of control,” or 
restless.  
Attempting to avoid sub-therapeutic concentrations, an increase in the efavirenz dosage 
from 600 mg to 800 mg has been recommended when concomitant treatment with rifampin 
is necessary (2004). A trial with 24 patients showed a reduction of efavirenz (600 mg) Cmax, 
AUC and Cmin of around 24, 22, and 25%, respectively, in  the presence of rifampin. (Lopez-
Cortes et al., 2002) The obtained Cmax, AUC and Cmin for efavirenz 600 mg in presence of 
rifampin, were 2.32 mg/L, 28.3 mg*h/L and 0.63 mg/L, respectively. However, the 
concentrations achieved with the combination of rifampin and efavirenz 800 mg are 
equivalent to values obtained with efavirenz 600 mg without rifampin. No improvement in 
virological efficacy with concomitant administration of rifampin and efavirenz 800 mg in 
relation to efavirenz Cmin and virological efficacy has been proven. (Manosuthi et al., 2005; 
Lopez-Cortes et al., 2006; Manosuthi et al., 2006)   
Moreover, the use of a higher dose may increase the risk for experiencing side effects, 
especially in patients from specific ethnic groups. African-Americans, Hispanics and Asians 
tend to have higher efavirenz concentrations than Caucasians. (Burger et al., 2006a; 
Ramachandran et al., 2009; Kwara et al., 2010)  
It is not clear if body weight is related to efavirenz plasma concentration or clearance, 
considering that studies have found contradictory results. Additional studies are needed 
regarding the impact of body weight, especially in patients weighing more than 60 kg. 
(Manosuthi et al., 2009b) What effect sex may play is contradictory as well. While some 
studies have found that females have higher plasma concentrations than males, other 
studies show no difference. (Gounden et al., 2010) 
Pharmacogenomics studies have been performed to elucidate the source of variability on 
efavirenz plasma concentrations. The effect of CYP2B6 polymorphisms on efavirenz 
concentrations was investigated in several studies. The polymorphism CYP2B6 516 G>T 
(CYP2B6*6) has the most data. The 516 T/T genotype was associated with lower efavirenz 
clearance, a longer half-life (~48 hours), and CNS toxicity. (Tsuchiya et al., 2004; Arab-
Alameddine et al., 2009) Thus, while efavirenz may be affected only mildly by the 
rifamycins the effects of certain covariates, specifically the role of pharmacogenetics, needs 
to be resolved.   
The concomitant administration of nevirapine with rifampin is known to reduce the exposure 
of nevirapine, affecting pharmacokinetic parameters such as Cmax, AUC, and Cmin. Despite this 
reduction various studies show drug concentrations to be within therapeutic range. (Ribera et 
al., 2001; Autar et al., 2005; Matteelli et al., 2009) However, a small study by Ramachandran et 
al. noted that 8 out of 13 patients had blood concentrations under the Cmin (3 µg/mL). 
(Ramachandran et al., 2009) They proposed the use of a higher dose (300 mg) for providing 
therapeutic drug concentrations to those patients; however, the study was composed of a 
small number of patients and conducted in a short period of time. The effect of rifampin on 
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nevirapine’s concentrations seems to decrease over time when nevirapine is used chronically 
with anti-TB drugs. Matteelli et al. conducted a study with 16 co-infected patients receiving 
HIV and TB treatment. (Mattelli et al., 2004) A reduction in the AUC of nevirapine by 25.6% 
was detected after four weeks of TB treatment while patients experienced a reduction of only 
7.5% after 10 weeks. The Cmax, AUC, and Cmin of nevirapine after 4 weeks were 4.8 μg/mL, 43.7 
μg*h/mL and 3.2 μg/mL, respectively.  
Manosuthi and collaborators conducted a study comparing the use of efavirenz or 
nevirapine with rifampin.(Manosuthi et al., 2009a) They found that the levels (Cmin) of 
efavirenz (600 mg) are less affected by rifampin than the levels of nevirapine (400 mg). The 
mean Cmin for week six were 4.27 mg/L (efavirenz) and 5.59 mg/L (nevirapine), and for 
week twelve:  3.54 mg/L (efavirenz) and 5.6 mg/L (nevirapine). 
3.2 Rifabutin 
Several medium-sized studies suggest that rifabutin may be as effective as rifampin for TB 
treatment. (Felten, 1987; Gonzalez-Montaner et al., 1994; McGregor et al., 1996) Schwander 
et al. first compared rifabutin to rifampin in co-infected HIV patients and found rifabutin to 
be as effective in the treatment of TB. Additionally, rifabutin treated patients in the study 
experienced earlier sputum conversion than their rifampin counterparts.  
Two issues arise with the use of rifabutin in AIDS patients. The first involves intermittent 
dosing and the second is in regards to drug interactions. In the pharmacokinetic sub-study 
of Tuberculosis Trials Consortium (TBTC) Study 23, patients were treated with twice-
weekly rifabutin and isoniazid. (Weiner et al., 2005) Eight of the 102 patients involved in the 
study developed rifamycin resistance with seven of these experiencing low serum 
concentrations of rifabutin. As with rifampin, due to the possibility of MTb developing 
resistance, highly intermittent dosing is not recommended in this patient population. 
As previously mentioned, rifabutin has less of an inductive effect on enzymes than rifampin 
(~40% less). (Burman et al., 1999) For this reason rifabutin is the preferred rifamycin for use 
in HIV patients when available. While less potent than rifampin and rifapentine, rifabutin 
still has several significant interactions with medications used to treat HIV or concomitant 
infections. Further complicating treatment with rifabutin is the fact that it is a CYP3A4 
substrate itself, leading to interactions with CYP inducers and inhibitors. For HIV patients 
requiring either a PI- or NNRTI-based therapy this poses substantial difficulty in finding a 
good therapeutic regimen. 
3.2.1 Rifabutin & the PIs 
Due to the potential of lopinavir-ritonavir to increase the serum concentrations of rifabutin 
the current recommendation by the CDC is to lower the dose of rifabutin from 300 mg thrice 
weekly to 150 mg thrice weekly or every other day when given together. There is recent 
evidence to suggest that this recommendation should be reconsidered.  
A pharmacokinetic study by Boulanger et al. measured the drug concentrations of rifabutin 
and lopinavir-ritonavir as well as the rifabutin metabolite, 25-desacetyl rifabutin, in HIV 
positive patients with active tuberculosis. (Boulanger et al., 2009) When rifabutin was 
administered at 150 mg thrice weekly in combination with lopinavir-ritonavir a majority of 
the patients had Cmax values below the normal range (0.3 to 0.9 ug/ml). PK-PD simulations 
by the authors suggested that when the two medications are administered together, 
rifabutin should be given daily, and that doses as high as 450 mg daily would be needed to 
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achieve free drug plasma concentrations at or above the minimum inhibitory concentration 
(MIC) for part of the dosing interval. The obtained rifabutin Cmax and AUC0-24 were 0.23 
μg/mL and 2.97 μg*h/mL, respectively. It should be noted that one patient developed 
rifamycin resistance during the study. 
A second study by Khachi et al. reported similar results. (Khachi et al., 2009) The authors 
monitored concentrations of an antiretroviral regimen containing lopinavir-ritonavir 
(400/100 mg) in combination with rifabutin 150 mg. Of the five patients studied, rifabutin 
levels were below target in all five patients (0.10 to 0.37 ug/ml). Two patients were 
reported to “deteriorate clinically” and had their rifabutin increased to 300 mg three times 
a week. Additionally, lopinavir-ritonavir concentrations were below targeted 
concentrations in two patients. While both studies are limited in scope due to small 
sample sizes, ten and five patients respectively, they indicate the need for a larger study 
to determine appropriate dosing.  
Darunavir and tipranavir result in increased rifabutin concentrations while rifabutin 
decreases their concentrations. (2004) The CDC recommends decreasing the dose of 
rifabutin by 75% to 150 mg every other day or 150 mg thrice weekly. However, these daily 
primarily reflect data from healthy volunteers, who tend to have more profound increases 
in rifabutin and 25-desacetyl-rifabutin concentrations than HIV-infected patients. As 
noted above, daily rifabutin doses, perhaps starting with 150 mg, may be preferred. This 
requires additional study. The remaining PIs (amprenavir, fosamprenavir, atazanavir, and 
indinavir) increase the AUC of rifabutin from 200 to 250% (again, primarily in healthy 
volunteers), while rifabutin does not appreciably alter any of their pharmacokinetics with 
the exception of indinavir. Indinavir is recommended to be increased to 1000 mg every 8 
hours while rifabutin should be decreased to 150 mg daily or 300 mg three times per 
week. 
Finally, saquinavir is contraindicated with rifabutin use unless boosted by ritonavir.  When 
rifabutin is used with unboosted saquinavir there is an approximate 40% increase in 
rifabutin AUC and a subsequent 40% decrease in saquinavir AUC.( 2007 Jul.)  Dosing is then 
recommended at 150 mg every other day or thrice weekly. All of these recommendations 
reflect mean changes, mostly from healthy volunteers, and results in individual HIV-
infected patients may be substantially different.(Gallicano et al., 2001) 
3.2.2 Rifabutin & the NNRTIs 
All of the NNRTIs are reported to interact with rifabutin to some degree. Delavirdine is 
contraindicated with rifabutin use due to an increase in rifabutin’s AUC (over 200%) and a 
decrease in delavirdine’s (80%)(2004). When rifabutin is prescribed with a PI boosted 
regimen, etravirine should be avoided because of the reduction in its concentration. 
(2008 Jan) This leaves efavirenz and nevirapine as the two NNRTIs which work best 
with rifabutin.  
When efavirenz is given the AUC of rifabutin is decreased substantially, necessitating a dose 
of 450 to 600 mg. Studies explored three times weekly dosing regimens; daily dosing with 
rifabutin 450 to 600 mg also would be acceptable with efavirenz (2004). The same is true of 
nevirapine regarding cell counts, but with a dose of 300 mg daily or thrice weekly for 
rifabutin. Again, three times weekly rifabutin may not be sufficient in all or even most 
patients, given the demonstrated risk of acquired rifamycin resistance in HIV-infected 
patients receiving intermittent rifabutin regimens. 
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Rifapentine is the latest rifamycin to be developed. A cyclopentyl derivative of rifampin, 
rifapentine has a longer half-life than rifampin and a 2 to 4-fold lower MIC.(Birmingham et 
al., 1978; Vital Durand et al., 1986) Unfortunately, rifapentine also inherited rifampin’s 
strong enzyme-inducing properties. Thanks to its extended half-life, rifapentine has been 
tested for intermittent dosing in the hopes of increasing patient compliance. Use of 
rifapentine is primarily reserved for the four month continuation phase of TB treatment, but 
is being studied for possible initial therapy. As with rifampin and rifabutin problems arose 
with highly intermittent dosing. TBTC Study 22 compared once-weekly rifapentine and 
isoniazid with twice-weekly rifampin and isoniazid in co-infected HIV/TB patients. 
(Vernon et al., 1999) HIV positive patients in the once-weekly rifapentine arm had higher 
rates of relapse than HIV positive patients in the twice-weekly rifampin arm. Four of the 
five patients who relapsed had acquired rifamycin monoresistance.  
4. Immune Reconstitution Inflammatory Syndrome (IRIS) 
In addition to drug interactions another common problem associated with co-infected 
patients which bears mentioning is the immune reconstitution inflammatory syndrome, 
otherwise known simply as IRIS.(Jevtovic et al., 2005; Tappuni, 2011)  IRIS most commonly 
occurs when ART is added to a patient’s regimen already being treated for TB. IRIS may 
occur anywhere from days to months following addition of ART. Symptoms are broad and 
may range from a mild fever to renal failure. Respiratory distress, expanding intracranial 
lesions and meningitis, lymphadenopathy, and skin lesions may develop also.  
The exact mechanism of IRIS is not completely known. Researchers believe that when ART 
begins to reduce HIV’s viral load the body’s immune system gradually recovers. This 
recovery leads to the immune system’s “awareness” of TB. The body overreacts to MTb 
antigens, releasing inflammatory cytokines and causing the aforementioned symptoms. Risk 
factors identified include: extrapulmonary TB, African-American race (one study), and early 
initiation of ART following TB therapy.(Breen et al., 2004; Burman et al., 2007) 
Steroids are most often used as initial treatment of IRIS. Some clinicians recommend 
prednisone 1 mg/kg/day or dexamethasone 8 to 16 mg/kg/day divided twice daily. 
(Sexton, 2011) Clinicians should initiate steroids on a case-by-case basis and be cautious 
about their use. Studies are mixed in regards to the mortality benefit of steroids and one 
study reported an increased incidence of Kaposi’s Sarcoma. (Hakim et al., 2000; Elliott et al., 
2004; Sharma et al., 2008) Other drug treatments which have been tried, but have little 
information regarding their use are: the non-steroidal anti-inflammatories (NSAIDs), the 
TNF-ǂ inhibitor, pentoxifylline, and thalidomide. (Marais et al., 2009) However, information 
regarding their efficacy is scarce.  
5. Pediatrics 
A relatively small amount of literature exists regarding rifamycin pharmacokinetics for 
young patients with HIV and TB. Schaaf et al. examined 54 pediatric patients, aged three 
months to 13 years, receiving rifampin, 21 of which had HIV. (Schaaf et al., 2009) In the 
study a majority of HIV positive and HIV negative patients experienced concentrations 
below what is considered the normal two hours Cmax range (8-24 ug/ml). While there was a 
trend for HIV positive patients toward a lower rifampin Cmax, no significant difference 
existed between the two groups.   
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Ren et al performed a study with 30 children aged seven months to four years and divided 
them in two groups. (Ren Y, 2008) One group composed of 15 HIV positive children without 
TB received lopinavir and ritonavir in a 4:1 ratio without rifampin. The second group of 15 
HIV positive children with TB were treated with an increased concentration of ritonavir to 
achieve 1:1 ratio of lopinavir-ritonavir (“super boosted” lopinavir). There was a reduction of 
the Cmax and AUC0-12 in the group that received additional ritonavir. However, there was no 
difference in the Cmin between both groups. The lopinavir Cmax, AUC0-12, and Cmin obtained 
for the regimen with rifampin were: 10.5 mg/L, 80.9 mg*h/L and 3.94 mg/L, respectively. 
The same researchers used population pharmacokinetic analysis to characterize the 
pharmacokinetic interactions and to examine the data from the Ren study.(Elsherbiny et al., 
2010) The adjustment of ritonavir to an equal proportion of the PI’s (that is, 1:1) was not able 
to entirely overcome the inductive effect that rifampin has over lopinavir. One of the 
reasons, as the authors point out, can be the fact that children aged one to four have more 
pronounced enzymatic activity, eliminating the lopinavir. However, the predicted trough 
concentrations by the model are over 1 ug/ml, indicating that with the additional ritonavir 
concentrations of lopinavir will be efficacious. More studies are necessary to verify the 
safety and efficacy of this combination. Studies also are needed regarding the use of 
rifabutin and rifapentine in the pediatric setting as data are limited. 
6. Therapeutic drug management  
Due to the extensive drug interactions, the overlapping side effects, and the length of 
treatment, a patient co-infected with TB and HIV has a more difficult time adhering to his or 
her regimen than patients with either disease state alone. TDM offers clinicians the ability to 
make a more informed therapeutic decision. Several studies have shown TDM to be of 
benefit in the TB patient. (Peloquin, 2002b) TDM for HIV medications has been studied in a 
series of small trials. Because most such trials have several additional variables, it is difficult 
to achieve statistical significance in these settings. However, it remains true that PIs are 
competitive, reversible inhibitors, so their continued presence is required for continued 
activity. Also, patients with HIV may have other opportunistic infections and experience 
malabsorption which can affect the concentration of TB drugs. (Kotler DP et al., 1984; Gillin 
JS et al., 1985; Peloquin, 2002b) TDM could be a useful tool to monitor the concentration in 
those patients. In a review of eight trials Kredo et al. reported that routine use of TDM is not 
warranted but TDM use in treatment-naïve patients initiated on a PI containing regimen 
may improve virological efficacy. (Kredo et al., 2009)  
In addition TDM may prove useful in determining which patients are experiencing 
malabsorption. Few studies have expressly looked at the malabsorption of anti-TB 
medications in HIV patients, and data are still accumulating, but evidence points toward the 
disease state negatively affecting concentrations of TB medications. A retrospective study of 
21 HIV/TB patients by Holland et al. demonstrates this effect. Out of 21 patients, 18 had 
two-hour concentrations of at least one drug (either, isoniazid, a rifamycin, or both) below 
the recommended range. (Holland et al., 2009) Current guidelines list TDM as an option for 
clinicians but further research in the area is needed. (CDC, 2007) 
TDM is recommended by many clinicians when both TB and HIV are treated concomitantly, 
especially when PIs and NNRTIs are used. However, TDM is not a substitute for clinical 
evaluation or directly observed treatment, but is useful to verify inadequate dose 
administration, or help solve drug-drug interaction problems. (Peloquin, 2002a) 
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Patients co-infected with HIV and TB have a difficult time adhering to their medication 
regimens due to many reasons. Even in those patients who are fortunate enough to receive 
appropriate treatment adherence is difficult. In addition to overlapping side effects and the 
possibility of IRIS, the drug regimens are lengthy and involve many drug interactions. 
Drug interactions between the rifamycins and the PIs and NNRTIs are varied and not 
easily quantified. Often, concentrations are unique to the individual in whom the 
interactions take place. One solution to this problem is to either use and/or develop new 
medications that have fewer interactions. While studies are underway with new (as well 
as older) anti-TB drugs a set timeline for their arrival is unknown. Additionally, a 
majority of patients reside in resource-poor settings where economics (or political or 
military strife) inhibit optimal care. 
Until new and improved regimens are developed a reasonable solution is to monitor the 
concentrations of HIV and anti-TB medications and alter the doses when warranted to 
achieve therapeutic success, i.e., TDM. TDM has been used in TB patients for many years 
and is considered a valuable tool by many clinicians in the successful treatment of their 
patients. 
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